Aparna M. Bhagavat, MD, FACC

Several trials have been conducted, and many more are yet to be completed, that have the goal of addressing whether intensive blood glucose control and intensive blood pressure (BP) control have any long-term benefit on all-cause mortality and major cardiovascular events. Contradictory data have been published with respect to the short- and long-term benefits of aggressive BP and blood glucose control versus conventional treatments for BP and glucose control. This review presents the main points of some of the important trials to date on this subject.

It is primarily the responsibility of parents, teachers, and health care professionals to be role models for the younger generation with respect to healthy eating and physical activity.

Aparna M. Bhagavat, MD, FACC, says gliptins have a promising role in the control of type 2 diabetes, as they decrease A1C without hypoglycemia, weight gain, or any obvious adverse effects on cardiovascular outcomes.